Tag: Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories launches migraine management wearable Nerivio in Germany
In an exciting development for migraine sufferers, Dr. Reddy’s Laboratories Ltd., a leader in the global pharmaceutical industry, has announced the launch of its groundbreaking, ... Read More
Dr. Reddy’s Laboratories launches Versavo in UK, marking a milestone in cancer treatment
Dr. Reddy’s Laboratories Ltd., a leading global pharmaceutical company, has made significant strides in cancer treatment with the introduction of Versavo (bevacizumab) in the United ... Read More
Dr. Reddy’s Laboratories expands wellness portfolio with MenoLabs acquisition
In a significant move within the healthcare industry, Dr. Reddy's Laboratories Ltd. has announced the acquisition of the MenoLabs business, a prominent player in women's ... Read More
Coya Therapeutics partners with Dr. Reddy’s for neurodegenerative disease therapy development
Coya Therapeutics, Inc. (NASDAQ: COYA), a clinical-stage biotechnology company, has entered into a worldwide agreement with Dr. Reddy’s Laboratories Limited, a global pharmaceutical leader, marking ... Read More
Dr. Reddy’s Laboratories introduces FDA-approved Nerivio for migraine management in India
Dr. Reddy’s Laboratories Ltd., a global pharmaceutical company, has announced the rollout of Nerivio in India. This state-of-the-art, United States Food and Drug Administration (USFDA) ... Read More
Dr. Reddy’s Q2 FY24 financial results show 9% YoY revenue growth
Dr. Reddy’s Laboratories Ltd., an Indian pharma major, has unveiled its robust performance metrics for the Q2 FY24, ending September 30, 2023. Under the guidelines ... Read More
Dr. Reddy’s Laboratories debuts generic version of KOMBIGLYZE XR in US
In a significant development for diabetes treatment in the U.S., Dr. Reddy's Laboratories has unveiled its Saxagliptin and Metformin Hydrochloride Extended-Release Tablets. This launch introduces ... Read More
FDA accepts review of Dr. Reddy’s biosimilar rituximab candidate, DRL_RI
Dr. Reddy's Laboratories, an Indian pharmaceutical company, announced that the US Food and Drug Administration (FDA) has accepted its Biologics License Application (BLA) for a ... Read More
Dr. Reddy’s launches RGenX to enter trade generics business in India
Dr. Reddy's Laboratories, an Indian pharmaceutical company, has announced its entry into the trade generics business in India with the launch of a dedicated division ... Read More
Dr. Reddy’s Tocilizumab biosimilar shows promising results in phase 1 trial
Dr. Reddy's Laboratories, an Indian pharmaceutical company, announced a significant milestone as its tocilizumab biosimilar candidate, DRL_TC, successfully met primary and secondary endpoints in a ... Read More